TY - JOUR
T1 - Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug
AU - Ibrahim, Mohamed Nabil
AU - Elfiky, Abdo Abdellah
N1 - KAUST Repository Item: Exported on 2022-06-21
Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged.
This publication acknowledges KAUST support, but has no KAUST affiliated authors.
PY - 2021/5/10
Y1 - 2021/5/10
N2 - The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
AB - The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
UR - http://hdl.handle.net/10754/679205
UR - https://thescipub.com/abstract/10.3844/ajbbsp.2021.205.207
UR - http://www.scopus.com/inward/record.url?scp=85107233257&partnerID=8YFLogxK
U2 - 10.3844/ajbbsp.2021.205.207
DO - 10.3844/ajbbsp.2021.205.207
M3 - Article
SN - 1558-6332
VL - 17
SP - 205
EP - 207
JO - American Journal of Biochemistry and Biotechnology
JF - American Journal of Biochemistry and Biotechnology
IS - 2
ER -
